The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery
Information source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hemostasis, Surgical
Intervention: Epoetin alfa (Drug); Standard of Care (Drug)
Phase: Phase 4
Status: Terminated
Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Official(s) and/or principal investigator(s): Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Summary
The primary purpose of the study is to compare the effect of perioperative (the time period
describing the duration of a participants surgical procedure) administration of PROCRIT to
that of Standard of Care (SOC) on the proportion of participants receiving pRBC (packed red
blood cells) transfusions (from the day of surgery to the day of hospital discharge) in
participants undergoing elective major abdominal and/or pelvic surgery. Standard of Care is
defined as the treatment of participants according to the hospital or institution's policy,
but where participants will not receive PROCRIT (Epoetin alfa) or any other
erythropoiesis-stimulating agents (ESAs) (agents that stimulate the production of red blood
cells in the bone marrow).
Clinical Details
Official title: An Open Label, Multicenter, Randomized, Controlled Study to Evaluate Efficacy and Safety of PROCRIT in Subjects Undergoing Elective Major Abdominal and/or Pelvic Surgery
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions
Secondary outcome: Hemoglobin Change From Baseline to End of StudyNumber of pRBC Units Transfused During Study Hospital Length of Stay
Detailed description:
This is a randomized (the study medication is assigned by chance), parallel-arm (each group
of participants will be treated at the same time), open-label (all people know the identity
of the intervention), multicenter study. The study consists of screening phase of 21 days,
treatment phase of 15 days, follow-up phase of 28 days. Approximately 110 participants
undergoing elective major abdominal and/or pelvic surgery will be enrolled. During the
Treatment Phase, eligible participants will be randomly assigned (participants are assigned
to a treatment group based on chance) in a 1: 1 ratio to either PROCRIT (Epoetin alfa) or the
Standard of Care (SOC) group that will not receive any erythropoiesis-stimulating agents
(ESAs). Participants will undergo surgery during the Treatment Phase. After surgery, all
participants will stay in the study for 4 days (or until hospital discharge) and followed
for an additional 28 days (Follow-up Phase). Safety evaluations will include assessment of
adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical
examination which will be monitored throughout the study. The duration of the study for each
participant will be approximately 64 days.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria: - Scheduled to undergo elective major abdominal and/or pelvic surgery
with anticipated significant perioperative ((the time period describing the duration of a
participants surgical procedure) blood loss (eg, greater than 500 cc and at increased risk
for blood transfusion) - Hemoglobin greater than 10 g/dL and less than or equal to 13 g/dL
at screening (Day - 13 [13 days prior to surgery] to Day -11) and baseline (Day -10) -
Patients with reproductive potential and their partners must practice an effective method
of birth control (eg, prescription oral contraceptives, contraceptive injections,
intrauterine device, double-barrier method, contraceptive patch, partner sterilization)
before entry and throughout the study - Female patients with reproductive potential must
have a negative urine pregnancy test within 7 days of the first dose of PROCRIT - Adequate
renal (kidney) and adequate hepatic (liver) function assessed within the 21-day screening
period Exclusion Criteria: - No severe Congestive Heart Failure (New York Heart
Association Class IV) - No known severe stable or unstable coronary artery disease, or
unstable angina - No history of deep venous thrombosis (DVT) or pulmonary embolus (PE)
within 12 months before study entry (prior superficial thrombophlebitis is not an
exclusion criterion) - No history of cerebrovascular accident (CVA), transient ischemic
attack (TIA), Acute coronary syndrome (unstable Angina, myocardial Infarction), or other
arterial thrombosis within 6 months before study entry - Not anticipated to donate
perioperative autologous blood or receive transfusions within 21 days prior to baseline or
to have greater than 6 transfusions perioperatively - No prior treatment with PROCRIT or
any erythropoiesis-stimulating agents (ESAs) within the previous month
Locations and Contacts
Additional Information
Starting date: August 2006
Last updated: July 2, 2013
|